Identification of primary mediastinal B-cell lymphomas with higher clonal dominance and poorer outcome using 5'RACE
There is a scarcity of data on the tumor B-cell receptor (BCR) repertoire and lymphoid microenvironment in primary mediastinal B-cell lymphoma (PMBL). We applied 5' rapid amplification of complimentary DNA ends (5'RACE) to tumor RNA samples from 137 patients with PMBL with available gene e...
Gespeichert in:
| Veröffentlicht in: | Blood advances 2025-01, Vol.9 (1), p.101 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 1 |
| container_start_page | 101 |
| container_title | Blood advances |
| container_volume | 9 |
| creator | Camus, Vincent Viennot, Mathieu Viailly, Pierre-Julien Drieux, Fanny Veresezan, Elena-Liana Bobée, Victor Rainville, Vinciane Bohers, Elodie Sesques, Pierre Haioun, Corinne Durot, Eric Bayaram, Michael Rossi, Cédric Martin, Laurent Penther, Dominique Kaltenbach, Sophie Bruneau, Julie Paillassa, Jérôme Tournilhac, Olivier Gower, Nicolas Willaume, Alexandre Antier, Chloé Renaud, Loïc Lévêque, Emilie Decazes, Pierre Becker, Stéphanie Tonnelet, David Gaulard, Philippe Tilly, Hervé Molina, Thierry Jo Traverse-Glehen, Alexandra Donzel, Marie Ruminy, Philippe Jardin, Fabrice |
| description | There is a scarcity of data on the tumor B-cell receptor (BCR) repertoire and lymphoid microenvironment in primary mediastinal B-cell lymphoma (PMBL). We applied 5' rapid amplification of complimentary DNA ends (5'RACE) to tumor RNA samples from 137 patients with PMBL with available gene expression profiling and next-generation sequencing data. We obtained 5'RACE results for 75 of the 137 (54.7%) patients with the following clinical characteristics: median age (range), 33 years (18-64); female, 53.3%; performance status score 0 to 1, 86.7%; stage I to II, 57.3%; first-line treatment with anti-CD20 plus doxorubicin-based chemotherapy, 100%. Among the 60 biopsies that expressed a productive BCR, we highlighted a strong somatic hypermutation profile, defined as 81.1% and >78.6% of all complementarity-determining region 3 sequences for IgVH and IgVL, respectively. When compared with other patients, this subgroup had similar clinical characteristics but a greater median allele frequency for all somatic variants, a decreased BCR diversity, and greater expression of PDL1/PDL2 and MS4A1 genes, suggesting greater tumoral infiltration. We confirmed this poorer prognosis in a multivariate model and in an independent validation cohort in which 6 of 37 (16%) PMBL patients exhibited HCD (PFS: HR, 12; OS: HR, 17). |
| doi_str_mv | 10.1182/bloodadvances.2024013723 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_3106732711</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3106732711</sourcerecordid><originalsourceid>FETCH-LOGICAL-p560-87e571eae0853b86b9c9fa98e8d95051cc5cc5e25eba236b590b4dc0d4e20e693</originalsourceid><addsrcrecordid>eNpNkFtLw0AQhRdRbKn9C7Jv-pK6l2w2-1hL1UJBkL6HvUyalSQbs4nivzfFCsLADMzH4ZyDEKZkRWnOHkwdgtPuU7cW4ooRlhLKJeMXaM5SyRMluLz8d8_QMsZ3QgiVGReKXaMZV0xxkpM5ijsH7eBLb_XgQ4tDibveN7r_xg04r-PgW13jx8RCXeP6u-mq0OiIv_xQ4cofK-ixrcOJcaGZ2MkU1q3DXQj99AvjYEMDeIy-PWJx97bebG_QVanrCMvzXqDD0_aweUn2r8-7zXqfdCIjSS5BSAoaSC64yTOjrCq1yiF3ShBBrRXTABNgNOOZEYqY1FniUmAEMsUX6P5XtuvDxwhxKBofTzF0C2GMBackk5xJSif09oyOZopdnCso_nriP5EQcCs</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3106732711</pqid></control><display><type>article</type><title>Identification of primary mediastinal B-cell lymphomas with higher clonal dominance and poorer outcome using 5'RACE</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Camus, Vincent ; Viennot, Mathieu ; Viailly, Pierre-Julien ; Drieux, Fanny ; Veresezan, Elena-Liana ; Bobée, Victor ; Rainville, Vinciane ; Bohers, Elodie ; Sesques, Pierre ; Haioun, Corinne ; Durot, Eric ; Bayaram, Michael ; Rossi, Cédric ; Martin, Laurent ; Penther, Dominique ; Kaltenbach, Sophie ; Bruneau, Julie ; Paillassa, Jérôme ; Tournilhac, Olivier ; Gower, Nicolas ; Willaume, Alexandre ; Antier, Chloé ; Renaud, Loïc ; Lévêque, Emilie ; Decazes, Pierre ; Becker, Stéphanie ; Tonnelet, David ; Gaulard, Philippe ; Tilly, Hervé ; Molina, Thierry Jo ; Traverse-Glehen, Alexandra ; Donzel, Marie ; Ruminy, Philippe ; Jardin, Fabrice</creator><creatorcontrib>Camus, Vincent ; Viennot, Mathieu ; Viailly, Pierre-Julien ; Drieux, Fanny ; Veresezan, Elena-Liana ; Bobée, Victor ; Rainville, Vinciane ; Bohers, Elodie ; Sesques, Pierre ; Haioun, Corinne ; Durot, Eric ; Bayaram, Michael ; Rossi, Cédric ; Martin, Laurent ; Penther, Dominique ; Kaltenbach, Sophie ; Bruneau, Julie ; Paillassa, Jérôme ; Tournilhac, Olivier ; Gower, Nicolas ; Willaume, Alexandre ; Antier, Chloé ; Renaud, Loïc ; Lévêque, Emilie ; Decazes, Pierre ; Becker, Stéphanie ; Tonnelet, David ; Gaulard, Philippe ; Tilly, Hervé ; Molina, Thierry Jo ; Traverse-Glehen, Alexandra ; Donzel, Marie ; Ruminy, Philippe ; Jardin, Fabrice</creatorcontrib><description>There is a scarcity of data on the tumor B-cell receptor (BCR) repertoire and lymphoid microenvironment in primary mediastinal B-cell lymphoma (PMBL). We applied 5' rapid amplification of complimentary DNA ends (5'RACE) to tumor RNA samples from 137 patients with PMBL with available gene expression profiling and next-generation sequencing data. We obtained 5'RACE results for 75 of the 137 (54.7%) patients with the following clinical characteristics: median age (range), 33 years (18-64); female, 53.3%; performance status score 0 to 1, 86.7%; stage I to II, 57.3%; first-line treatment with anti-CD20 plus doxorubicin-based chemotherapy, 100%. Among the 60 biopsies that expressed a productive BCR, we highlighted a strong somatic hypermutation profile, defined as <98% identity to the germ line sequence, with 58 (96.7%) patients carrying mutated IgVH. We then identified a subgroup of 12 of the 75 patients (16%) with a worse prognosis (progression-free survival [PFS]: hazard ratio [HR], 17; overall survival [OS]: HR, 21) that was associated with the highest clonal dominance (HCD) status, defined as the dominant clonotype representing >81.1% and >78.6% of all complementarity-determining region 3 sequences for IgVH and IgVL, respectively. When compared with other patients, this subgroup had similar clinical characteristics but a greater median allele frequency for all somatic variants, a decreased BCR diversity, and greater expression of PDL1/PDL2 and MS4A1 genes, suggesting greater tumoral infiltration. We confirmed this poorer prognosis in a multivariate model and in an independent validation cohort in which 6 of 37 (16%) PMBL patients exhibited HCD (PFS: HR, 12; OS: HR, 17).</description><identifier>ISSN: 2473-9537</identifier><identifier>EISSN: 2473-9537</identifier><identifier>DOI: 10.1182/bloodadvances.2024013723</identifier><identifier>PMID: 39293080</identifier><language>eng</language><publisher>United States</publisher><subject>Adolescent ; Adult ; Female ; Humans ; Lymphoma, B-Cell - genetics ; Lymphoma, B-Cell - mortality ; Lymphoma, B-Cell - pathology ; Male ; Mediastinal Neoplasms - genetics ; Mediastinal Neoplasms - mortality ; Mediastinal Neoplasms - pathology ; Middle Aged ; Prognosis ; Receptors, Antigen, B-Cell - genetics ; Young Adult</subject><ispartof>Blood advances, 2025-01, Vol.9 (1), p.101</ispartof><rights>2024 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><orcidid>0000-0002-9438-621X ; 0000-0002-1559-007X ; 0000-0001-5323-9910 ; 0000-0001-5519-8489 ; 0000-0002-3929-9754 ; 0000-0001-8264-822X ; 0000-0001-9168-576X ; 0000-0002-5797-5744 ; 0000-0002-8609-0611 ; 0000-0003-3463-0089 ; 0000-0001-7213-9464 ; 0000-0003-3717-7961 ; 0000-0002-9357-4542</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,860,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39293080$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Camus, Vincent</creatorcontrib><creatorcontrib>Viennot, Mathieu</creatorcontrib><creatorcontrib>Viailly, Pierre-Julien</creatorcontrib><creatorcontrib>Drieux, Fanny</creatorcontrib><creatorcontrib>Veresezan, Elena-Liana</creatorcontrib><creatorcontrib>Bobée, Victor</creatorcontrib><creatorcontrib>Rainville, Vinciane</creatorcontrib><creatorcontrib>Bohers, Elodie</creatorcontrib><creatorcontrib>Sesques, Pierre</creatorcontrib><creatorcontrib>Haioun, Corinne</creatorcontrib><creatorcontrib>Durot, Eric</creatorcontrib><creatorcontrib>Bayaram, Michael</creatorcontrib><creatorcontrib>Rossi, Cédric</creatorcontrib><creatorcontrib>Martin, Laurent</creatorcontrib><creatorcontrib>Penther, Dominique</creatorcontrib><creatorcontrib>Kaltenbach, Sophie</creatorcontrib><creatorcontrib>Bruneau, Julie</creatorcontrib><creatorcontrib>Paillassa, Jérôme</creatorcontrib><creatorcontrib>Tournilhac, Olivier</creatorcontrib><creatorcontrib>Gower, Nicolas</creatorcontrib><creatorcontrib>Willaume, Alexandre</creatorcontrib><creatorcontrib>Antier, Chloé</creatorcontrib><creatorcontrib>Renaud, Loïc</creatorcontrib><creatorcontrib>Lévêque, Emilie</creatorcontrib><creatorcontrib>Decazes, Pierre</creatorcontrib><creatorcontrib>Becker, Stéphanie</creatorcontrib><creatorcontrib>Tonnelet, David</creatorcontrib><creatorcontrib>Gaulard, Philippe</creatorcontrib><creatorcontrib>Tilly, Hervé</creatorcontrib><creatorcontrib>Molina, Thierry Jo</creatorcontrib><creatorcontrib>Traverse-Glehen, Alexandra</creatorcontrib><creatorcontrib>Donzel, Marie</creatorcontrib><creatorcontrib>Ruminy, Philippe</creatorcontrib><creatorcontrib>Jardin, Fabrice</creatorcontrib><title>Identification of primary mediastinal B-cell lymphomas with higher clonal dominance and poorer outcome using 5'RACE</title><title>Blood advances</title><addtitle>Blood Adv</addtitle><description>There is a scarcity of data on the tumor B-cell receptor (BCR) repertoire and lymphoid microenvironment in primary mediastinal B-cell lymphoma (PMBL). We applied 5' rapid amplification of complimentary DNA ends (5'RACE) to tumor RNA samples from 137 patients with PMBL with available gene expression profiling and next-generation sequencing data. We obtained 5'RACE results for 75 of the 137 (54.7%) patients with the following clinical characteristics: median age (range), 33 years (18-64); female, 53.3%; performance status score 0 to 1, 86.7%; stage I to II, 57.3%; first-line treatment with anti-CD20 plus doxorubicin-based chemotherapy, 100%. Among the 60 biopsies that expressed a productive BCR, we highlighted a strong somatic hypermutation profile, defined as <98% identity to the germ line sequence, with 58 (96.7%) patients carrying mutated IgVH. We then identified a subgroup of 12 of the 75 patients (16%) with a worse prognosis (progression-free survival [PFS]: hazard ratio [HR], 17; overall survival [OS]: HR, 21) that was associated with the highest clonal dominance (HCD) status, defined as the dominant clonotype representing >81.1% and >78.6% of all complementarity-determining region 3 sequences for IgVH and IgVL, respectively. When compared with other patients, this subgroup had similar clinical characteristics but a greater median allele frequency for all somatic variants, a decreased BCR diversity, and greater expression of PDL1/PDL2 and MS4A1 genes, suggesting greater tumoral infiltration. We confirmed this poorer prognosis in a multivariate model and in an independent validation cohort in which 6 of 37 (16%) PMBL patients exhibited HCD (PFS: HR, 12; OS: HR, 17).</description><subject>Adolescent</subject><subject>Adult</subject><subject>Female</subject><subject>Humans</subject><subject>Lymphoma, B-Cell - genetics</subject><subject>Lymphoma, B-Cell - mortality</subject><subject>Lymphoma, B-Cell - pathology</subject><subject>Male</subject><subject>Mediastinal Neoplasms - genetics</subject><subject>Mediastinal Neoplasms - mortality</subject><subject>Mediastinal Neoplasms - pathology</subject><subject>Middle Aged</subject><subject>Prognosis</subject><subject>Receptors, Antigen, B-Cell - genetics</subject><subject>Young Adult</subject><issn>2473-9537</issn><issn>2473-9537</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2025</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpNkFtLw0AQhRdRbKn9C7Jv-pK6l2w2-1hL1UJBkL6HvUyalSQbs4nivzfFCsLADMzH4ZyDEKZkRWnOHkwdgtPuU7cW4ooRlhLKJeMXaM5SyRMluLz8d8_QMsZ3QgiVGReKXaMZV0xxkpM5ijsH7eBLb_XgQ4tDibveN7r_xg04r-PgW13jx8RCXeP6u-mq0OiIv_xQ4cofK-ixrcOJcaGZ2MkU1q3DXQj99AvjYEMDeIy-PWJx97bebG_QVanrCMvzXqDD0_aweUn2r8-7zXqfdCIjSS5BSAoaSC64yTOjrCq1yiF3ShBBrRXTABNgNOOZEYqY1FniUmAEMsUX6P5XtuvDxwhxKBofTzF0C2GMBackk5xJSif09oyOZopdnCso_nriP5EQcCs</recordid><startdate>20250114</startdate><enddate>20250114</enddate><creator>Camus, Vincent</creator><creator>Viennot, Mathieu</creator><creator>Viailly, Pierre-Julien</creator><creator>Drieux, Fanny</creator><creator>Veresezan, Elena-Liana</creator><creator>Bobée, Victor</creator><creator>Rainville, Vinciane</creator><creator>Bohers, Elodie</creator><creator>Sesques, Pierre</creator><creator>Haioun, Corinne</creator><creator>Durot, Eric</creator><creator>Bayaram, Michael</creator><creator>Rossi, Cédric</creator><creator>Martin, Laurent</creator><creator>Penther, Dominique</creator><creator>Kaltenbach, Sophie</creator><creator>Bruneau, Julie</creator><creator>Paillassa, Jérôme</creator><creator>Tournilhac, Olivier</creator><creator>Gower, Nicolas</creator><creator>Willaume, Alexandre</creator><creator>Antier, Chloé</creator><creator>Renaud, Loïc</creator><creator>Lévêque, Emilie</creator><creator>Decazes, Pierre</creator><creator>Becker, Stéphanie</creator><creator>Tonnelet, David</creator><creator>Gaulard, Philippe</creator><creator>Tilly, Hervé</creator><creator>Molina, Thierry Jo</creator><creator>Traverse-Glehen, Alexandra</creator><creator>Donzel, Marie</creator><creator>Ruminy, Philippe</creator><creator>Jardin, Fabrice</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-9438-621X</orcidid><orcidid>https://orcid.org/0000-0002-1559-007X</orcidid><orcidid>https://orcid.org/0000-0001-5323-9910</orcidid><orcidid>https://orcid.org/0000-0001-5519-8489</orcidid><orcidid>https://orcid.org/0000-0002-3929-9754</orcidid><orcidid>https://orcid.org/0000-0001-8264-822X</orcidid><orcidid>https://orcid.org/0000-0001-9168-576X</orcidid><orcidid>https://orcid.org/0000-0002-5797-5744</orcidid><orcidid>https://orcid.org/0000-0002-8609-0611</orcidid><orcidid>https://orcid.org/0000-0003-3463-0089</orcidid><orcidid>https://orcid.org/0000-0001-7213-9464</orcidid><orcidid>https://orcid.org/0000-0003-3717-7961</orcidid><orcidid>https://orcid.org/0000-0002-9357-4542</orcidid></search><sort><creationdate>20250114</creationdate><title>Identification of primary mediastinal B-cell lymphomas with higher clonal dominance and poorer outcome using 5'RACE</title><author>Camus, Vincent ; Viennot, Mathieu ; Viailly, Pierre-Julien ; Drieux, Fanny ; Veresezan, Elena-Liana ; Bobée, Victor ; Rainville, Vinciane ; Bohers, Elodie ; Sesques, Pierre ; Haioun, Corinne ; Durot, Eric ; Bayaram, Michael ; Rossi, Cédric ; Martin, Laurent ; Penther, Dominique ; Kaltenbach, Sophie ; Bruneau, Julie ; Paillassa, Jérôme ; Tournilhac, Olivier ; Gower, Nicolas ; Willaume, Alexandre ; Antier, Chloé ; Renaud, Loïc ; Lévêque, Emilie ; Decazes, Pierre ; Becker, Stéphanie ; Tonnelet, David ; Gaulard, Philippe ; Tilly, Hervé ; Molina, Thierry Jo ; Traverse-Glehen, Alexandra ; Donzel, Marie ; Ruminy, Philippe ; Jardin, Fabrice</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p560-87e571eae0853b86b9c9fa98e8d95051cc5cc5e25eba236b590b4dc0d4e20e693</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2025</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Female</topic><topic>Humans</topic><topic>Lymphoma, B-Cell - genetics</topic><topic>Lymphoma, B-Cell - mortality</topic><topic>Lymphoma, B-Cell - pathology</topic><topic>Male</topic><topic>Mediastinal Neoplasms - genetics</topic><topic>Mediastinal Neoplasms - mortality</topic><topic>Mediastinal Neoplasms - pathology</topic><topic>Middle Aged</topic><topic>Prognosis</topic><topic>Receptors, Antigen, B-Cell - genetics</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Camus, Vincent</creatorcontrib><creatorcontrib>Viennot, Mathieu</creatorcontrib><creatorcontrib>Viailly, Pierre-Julien</creatorcontrib><creatorcontrib>Drieux, Fanny</creatorcontrib><creatorcontrib>Veresezan, Elena-Liana</creatorcontrib><creatorcontrib>Bobée, Victor</creatorcontrib><creatorcontrib>Rainville, Vinciane</creatorcontrib><creatorcontrib>Bohers, Elodie</creatorcontrib><creatorcontrib>Sesques, Pierre</creatorcontrib><creatorcontrib>Haioun, Corinne</creatorcontrib><creatorcontrib>Durot, Eric</creatorcontrib><creatorcontrib>Bayaram, Michael</creatorcontrib><creatorcontrib>Rossi, Cédric</creatorcontrib><creatorcontrib>Martin, Laurent</creatorcontrib><creatorcontrib>Penther, Dominique</creatorcontrib><creatorcontrib>Kaltenbach, Sophie</creatorcontrib><creatorcontrib>Bruneau, Julie</creatorcontrib><creatorcontrib>Paillassa, Jérôme</creatorcontrib><creatorcontrib>Tournilhac, Olivier</creatorcontrib><creatorcontrib>Gower, Nicolas</creatorcontrib><creatorcontrib>Willaume, Alexandre</creatorcontrib><creatorcontrib>Antier, Chloé</creatorcontrib><creatorcontrib>Renaud, Loïc</creatorcontrib><creatorcontrib>Lévêque, Emilie</creatorcontrib><creatorcontrib>Decazes, Pierre</creatorcontrib><creatorcontrib>Becker, Stéphanie</creatorcontrib><creatorcontrib>Tonnelet, David</creatorcontrib><creatorcontrib>Gaulard, Philippe</creatorcontrib><creatorcontrib>Tilly, Hervé</creatorcontrib><creatorcontrib>Molina, Thierry Jo</creatorcontrib><creatorcontrib>Traverse-Glehen, Alexandra</creatorcontrib><creatorcontrib>Donzel, Marie</creatorcontrib><creatorcontrib>Ruminy, Philippe</creatorcontrib><creatorcontrib>Jardin, Fabrice</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Blood advances</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Camus, Vincent</au><au>Viennot, Mathieu</au><au>Viailly, Pierre-Julien</au><au>Drieux, Fanny</au><au>Veresezan, Elena-Liana</au><au>Bobée, Victor</au><au>Rainville, Vinciane</au><au>Bohers, Elodie</au><au>Sesques, Pierre</au><au>Haioun, Corinne</au><au>Durot, Eric</au><au>Bayaram, Michael</au><au>Rossi, Cédric</au><au>Martin, Laurent</au><au>Penther, Dominique</au><au>Kaltenbach, Sophie</au><au>Bruneau, Julie</au><au>Paillassa, Jérôme</au><au>Tournilhac, Olivier</au><au>Gower, Nicolas</au><au>Willaume, Alexandre</au><au>Antier, Chloé</au><au>Renaud, Loïc</au><au>Lévêque, Emilie</au><au>Decazes, Pierre</au><au>Becker, Stéphanie</au><au>Tonnelet, David</au><au>Gaulard, Philippe</au><au>Tilly, Hervé</au><au>Molina, Thierry Jo</au><au>Traverse-Glehen, Alexandra</au><au>Donzel, Marie</au><au>Ruminy, Philippe</au><au>Jardin, Fabrice</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Identification of primary mediastinal B-cell lymphomas with higher clonal dominance and poorer outcome using 5'RACE</atitle><jtitle>Blood advances</jtitle><addtitle>Blood Adv</addtitle><date>2025-01-14</date><risdate>2025</risdate><volume>9</volume><issue>1</issue><spage>101</spage><pages>101-</pages><issn>2473-9537</issn><eissn>2473-9537</eissn><abstract>There is a scarcity of data on the tumor B-cell receptor (BCR) repertoire and lymphoid microenvironment in primary mediastinal B-cell lymphoma (PMBL). We applied 5' rapid amplification of complimentary DNA ends (5'RACE) to tumor RNA samples from 137 patients with PMBL with available gene expression profiling and next-generation sequencing data. We obtained 5'RACE results for 75 of the 137 (54.7%) patients with the following clinical characteristics: median age (range), 33 years (18-64); female, 53.3%; performance status score 0 to 1, 86.7%; stage I to II, 57.3%; first-line treatment with anti-CD20 plus doxorubicin-based chemotherapy, 100%. Among the 60 biopsies that expressed a productive BCR, we highlighted a strong somatic hypermutation profile, defined as <98% identity to the germ line sequence, with 58 (96.7%) patients carrying mutated IgVH. We then identified a subgroup of 12 of the 75 patients (16%) with a worse prognosis (progression-free survival [PFS]: hazard ratio [HR], 17; overall survival [OS]: HR, 21) that was associated with the highest clonal dominance (HCD) status, defined as the dominant clonotype representing >81.1% and >78.6% of all complementarity-determining region 3 sequences for IgVH and IgVL, respectively. When compared with other patients, this subgroup had similar clinical characteristics but a greater median allele frequency for all somatic variants, a decreased BCR diversity, and greater expression of PDL1/PDL2 and MS4A1 genes, suggesting greater tumoral infiltration. We confirmed this poorer prognosis in a multivariate model and in an independent validation cohort in which 6 of 37 (16%) PMBL patients exhibited HCD (PFS: HR, 12; OS: HR, 17).</abstract><cop>United States</cop><pmid>39293080</pmid><doi>10.1182/bloodadvances.2024013723</doi><orcidid>https://orcid.org/0000-0002-9438-621X</orcidid><orcidid>https://orcid.org/0000-0002-1559-007X</orcidid><orcidid>https://orcid.org/0000-0001-5323-9910</orcidid><orcidid>https://orcid.org/0000-0001-5519-8489</orcidid><orcidid>https://orcid.org/0000-0002-3929-9754</orcidid><orcidid>https://orcid.org/0000-0001-8264-822X</orcidid><orcidid>https://orcid.org/0000-0001-9168-576X</orcidid><orcidid>https://orcid.org/0000-0002-5797-5744</orcidid><orcidid>https://orcid.org/0000-0002-8609-0611</orcidid><orcidid>https://orcid.org/0000-0003-3463-0089</orcidid><orcidid>https://orcid.org/0000-0001-7213-9464</orcidid><orcidid>https://orcid.org/0000-0003-3717-7961</orcidid><orcidid>https://orcid.org/0000-0002-9357-4542</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2473-9537 |
| ispartof | Blood advances, 2025-01, Vol.9 (1), p.101 |
| issn | 2473-9537 2473-9537 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3106732711 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Alma/SFX Local Collection |
| subjects | Adolescent Adult Female Humans Lymphoma, B-Cell - genetics Lymphoma, B-Cell - mortality Lymphoma, B-Cell - pathology Male Mediastinal Neoplasms - genetics Mediastinal Neoplasms - mortality Mediastinal Neoplasms - pathology Middle Aged Prognosis Receptors, Antigen, B-Cell - genetics Young Adult |
| title | Identification of primary mediastinal B-cell lymphomas with higher clonal dominance and poorer outcome using 5'RACE |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T17%3A42%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Identification%20of%20primary%20mediastinal%20B-cell%20lymphomas%20with%20higher%20clonal%20dominance%20and%20poorer%20outcome%20using%205'RACE&rft.jtitle=Blood%20advances&rft.au=Camus,%20Vincent&rft.date=2025-01-14&rft.volume=9&rft.issue=1&rft.spage=101&rft.pages=101-&rft.issn=2473-9537&rft.eissn=2473-9537&rft_id=info:doi/10.1182/bloodadvances.2024013723&rft_dat=%3Cproquest_pubme%3E3106732711%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3106732711&rft_id=info:pmid/39293080&rfr_iscdi=true |